Trials / Completed
CompletedNCT00469443
Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC
A Randomized Phase III Study of Irinotecan Plus 5-fluorouracil Plus Leucovorin and Bevacizumab (FOLFIRI+Avastin) Versus Irinotecan Plus Capecitabine and Bevacizumab (XELIRI+Avastin) as 1st Line Treatment of Locally Advanced or Metastatic Colorectal Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 330 (estimated)
- Sponsor
- Hellenic Oncology Research Group · Academic / Other
- Sex
- All
- Age
- 18 Years – 72 Years
- Healthy volunteers
- Not accepted
Summary
This phase III study will compare two combinations of irinotecan, Folfiri versus Xeliri, with the addition of Avastin as 1st line treatment of colorectal cancer.
Detailed description
There is no data of comparison for Folfiri and Xeliri regimens. The reported data demonstrated that the addition of Avastin in the combination of irinotecan/bolus 5-FU/LV has significant improvement of overall survival. Further analysis of these results showed that patients receiving irinotecan in combination with Avastin, as 1st line treatment and oxaliplatin with Avastin, as second line treatment, have median overall survival 25, 1 months, which is the longest survival that has been reported.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Irinotecan | Irinotecan 150mg/m2 IV on day 1 every 2 weeks for 10 cycles |
| DRUG | 5-Fluorouracil | 5-Fluorouracil 400 mg/m2 infused over 10 min IV and 5-FU 600 mg/m2 infused over 22 hours IV, on Day 1 and 2 (De Grammont regimen), every 2 weeks for 10 cycles |
| DRUG | Leucovorin | Leucovorin 200 mg/m2 infused over 2 hours IV, on day 1 and 2 every 2 weeks for 10 cycles |
| DRUG | Capecitabine | Capecitabine 2000mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles |
| DRUG | Bevacizumab | Bevacizumab 5mg/kg IV on day 1 every 2 weeks for 10 cycles |
| DRUG | Bevacizumab | Bevacizumab 7,5mg/kg IV on day 1 every 3 weeks for 6 cycles |
| DRUG | Irinotecan | Irinotecan 250mg/m2 IV on day 1 every 3 weeks for 6 cycles |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2010-02-01
- Completion
- 2010-02-01
- First posted
- 2007-05-04
- Last updated
- 2010-08-19
Locations
8 sites across 1 country: Greece
Source: ClinicalTrials.gov record NCT00469443. Inclusion in this directory is not an endorsement.